Drug Profile
Research programme: phosphopeptide-specific T-cell receptors - Agenus
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Agenus
- Class Antineoplastics; Cell therapies
- Mechanism of Action Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 06 Sep 2017 Preclinical trials in Cancer in Switzerland (unspecified route)
- 06 Sep 2017 Efficacy data from a preclinical trial in Cancer presented at the 3rd International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)